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A B S T R A C T
It is estimated that over half the population of the European Union (EU) is overweight or obese due to an
imbalance between energy expenditure and energy intake; this is related to an obesogenic environment
of sociocultural, economic and marketing challenges to the control of body weight. Excess body fat is
associated with nine cancer sites – oesophagus, colorectum, gall bladder, pancreas, postmenopausal
breast, endometrium, ovary, kidney and prostate (advanced) – and 4–38% of these cancers (depending on
site and gender) can be attributed to overweight/obesity status. Metabolic alterations which accompany
excess body weight are accompanied by increased levels of inﬂammation, insulin, oestrogens and other
hormonal factors. There are some indications that intentional weight loss is associated with reduced
cancer incidence (notably in postmenopausal breast and endometrial cancers). Excess body weight is
also a risk factor for several other diseases, including diabetes and heart disease, and is related to higher
risk of premature death.
In reviewing the current evidence related to excess body fat and cancer, the European Code against
Cancer Nutrition Working Group has developed the following recommendation: ‘Take action to be a
healthy body weight’.
 2015 International Agency for Research on Cancer; Licensee ELSEVIER Ltd https://creativecom-
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1.1. European prevalence of overweight and obesity
In 2012 over half the population of the EuropeanUnion (EU)was
estimated to be overweight [1], and one person in six was obese
[2]. In adults, the proportion of men who are obese is between 8%
(Romania) and 26% (Hungary), and the proportion of women who
are obese is between 8% (Romania) and 30% (Hungary) (Fig. 1).
1.1.1. Overweight and obesity by age group and level of education
The proportion of people who are overweight or obese is higher
in older than in younger people (Fig. 2). At ages 18–24, the
proportion of men who are overweight or obese is below 30% in all
countries except the Czech Republic, Cyprus, Poland, Slovenia and
the UK, and the proportion of womenwho are overweight or obese
is below 20% in all countries except the UK (Figs. 3 and 4). At ages
65–74, the proportion of men who are overweight or obese is
above 60% in all countries, and the proportion of women who are
overweight or obese is above 60% in all countries except Belgium,
France, Italy and Romania (Figs. 2 and 3).
Among adolescents (15-year-olds) in EU member states, boys
report excess weight more often than girls; one in six boys and one
[(Fig._1)TD$FIG]
Fig. 1. Prevalence of obesity among adults in Europe, 2012 (or nearest year). Calculatio
Publishing’ [2].in 10 girls report being overweight or obese. More than 15% of
adolescents in southern European countries (Greece, Italy, Portugal
and Spain), as well as in Croatia, Iceland, Luxembourg and Slovenia,
report being overweight or obese. Fewer than 10% of children in
Latvia and Lithuania, as well as in Denmark, France and the
Netherlands, report being overweight or obese (Fig. 4).
The proportion of overweight and obese people varies with
educational level. In women the pattern is clear in that the
proportion of obese or overweight women falls as the educational
level rises (Fig. 5). In men, however, the educational level with the
highest prevalence of overweight and obesity varies between
countries, with some countries having the highest proportion in
the least educated men, some having the highest proportion in the
most educated, and some having the highest proportion in those
with a medium level of education (Fig. 6).
1.2. Deﬁnition of overweight, obesity, body fatness and waist
circumference
When energy intake is equal to energy expenditure, then energy
balance is reached and the body neither gains nor loses weight. If
excess energy intake or low energy expenditure occurs then
weight gain will follow, mostly in the form of fat storage. Body fatns provided by the OECD based on ‘OECD. Health at a glance: Europe 2012. OECD
[(Fig._2)TD$FIG]
Fig. 2. Prevalence of overweight and obesity in men in Europe by age. Calculations provided by the Eurostat database [3].
A.S. Anderson et al. / Cancer Epidemiology 39S (2015) S34–S45S36stores cannot be easily measured, so body mass index (BMI) is
commonly used as a proxy. BMI is assessed as weight (in kg)
divided by the square of height (in m2). This measure is generally a
good index of obesity, but can bemisleading for people who have a
very highmuscle mass because they will have a high BMI but not a
highmass of stored fat. Increasingly, it is also recognised that intra-
abdominal fat (visceral fat) assessed by waist circumference is a[(Fig._3)TD$FIG]
Fig. 3. Prevalence of overweight and obesity in women in Europe by age. Calculations p
portal/health/health_status_determinants/data/database).good indicator of disease risk, and both BMI and waist circumfer-
ence are informative in body fat assessment.
The principal BMI cut-offs deﬁned by the World Health
Organization (WHO) are overweight (25.00–29.99 kg/m2) and
obesity (30.00 kg/m2 or more) (Table 1). These categories have
been widely applied, although the associations between BMI,
percentage of body fat, body fat distribution and diseaserovided by the Eurostat database [3] (http://epp.eurostat.ec.europa.eu/portal/page/
[(Fig._4)TD$FIG]
Fig. 4. Prevalence of overweight and obesity among adolescents in Europe, 2009–2010. Calculations provided by the OECD based on ‘OECD. Health at a glance: Europe
2014. OECD Publishing’ [2].
A.S. Anderson et al. / Cancer Epidemiology 39S (2015) S34–S45 S37risk are continuous and curvilinear, and differ between
populations.
Abdominal obesity can be assessed using a standard protocol
formeasuringwaist circumference (Fig. 7). Thewaist–hip ratio (i.e.
the waist circumference divided by the hip circumference) is a
measure of body fat distribution; a high waist–hip ratio indicates
that proportionally more fat is stored around the middle of the
body, both subcutaneously and within the abdominal cavity, than
around the hips. The waist–hip ratio has been shown to be
positively associated with risk for several types of cancer. Gender-
speciﬁc cuts-offs for increased disease risk as indicated by fat
storage distribution have been proposed by WHO (Table 2).
1.3. Modiﬁable lifestyle factors and environmental factors associated
with overweight and obesity
An unhealthy weight is often seen as a result of individual
choices with regard to diet, physical activity and lifestyle, all of
which can be controlled and modiﬁed to some extent. However, it
is recognised that people live in an obesogenic environment ofsociocultural, economic and marketing challenges to the achieve-
ment of healthy ways of life [4]. Low cost, widely available energy-
dense food and drink, combined with few opportunities to easily
engage in work, home and leisure physical activity, stack the odds
against successful weight management for the majority of the
population [5].
Excessive intake of energy-dense foods and drinks is a major
factor in the development of obesity from infancy onwards. Dietary
habits including consumption of sugary drinks [6], fast foods and
energy-dense foods (such as processed foods which are high in
saturated fat, sugar and salt) [7] will increase the likelihood of
positive energy balance and excessive fat storage. Regular
consumption of large portions of foods with energy density
>225 kcals/100 g (941 kJ/100 g) are associated with increased risk
of weight gain [7].
Regular, sustained physical activity of all types protects against
weight gain, overweight and obesity [7]. In addition, large amounts
of sedentary behaviour (notably television viewing) are likely to
increase the risk for weight gain [7]. A review by Boulos et al. [8] on
weight gain suggests that television viewing is a substitute for
[(Fig._5)TD$FIG]
Fig. 5. Prevalence of overweight and obesity in women in Europe by level of education. Calculations provided by the Eurostat database [3] (http://epp.eurostat.ec.europa.eu/
portal/page/portal/health/health_status_determinants/data/database).
A.S. Anderson et al. / Cancer Epidemiology 39S (2015) S34–S45S38being physically active as well as stimulating food intake and
‘mindless eating’ through advertising and product placements.
1.3.1. Breastfeeding
Infants who are breastfed appear to have a reduced risk of
obesity in childhood and adolescence compared to those who are[(Fig._6)TD$FIG]
Fig. 6. Prevalence of overweight and obesity in men in Europe by level of education. Ca
portal/page/portal/health/health_status_determinants/data/database).formula fed. A recent review [9] of prospective studies with
children up to the age of 16 reported a 15% decrease in the odds of
childhood obesity for breastfed infants. Such effects are likely to
persist into adulthood [10]. However, it is recognised that potential
confounders (e.g. education of themother)may not have been fully
accounted for in this analysis. In addition, Ip et al. [11] noted thatlculations provided by the Eurostat database [3] (http://epp.eurostat.ec.europa.eu/
Table 1
The international classiﬁcation of adult underweight, overweight and obesity
according to body mass index (BMI) [90].
Classiﬁcation BMI (kg/m2)
Principal cut-off
points
Additional cut-off
points
Underweight <18.50 <18.50
Normal range 18.50–24.99 18.50–22.99
23.00–24.99
Overweight 25.00 25.00
Pre-obese 25.00–29.99 25.00–27.49
27.50–29.99
Obese 30.00 30.00
Obese class I 30.00–34.99 30.00–32.49
32.50–34.99
Obese class II 35.00–39.99 35.00–37.49
37.50–39.99
Obese class III 40.00 40.00
Adapted from WHO (1995, 2000, 2004).
A.S. Anderson et al. / Cancer Epidemiology 39S (2015) S34–S45 S39observed associations between breastfeeding and a reduced risk of
obesity may reﬂect selective reporting and/or publication bias. In
most studies the exclusivity of breastfeeding is not described. The
mechanisms by which breastfeeding may impact on weight
development have not been identiﬁed, although it is notable that
breastfed infants consume less total energy and less protein than
formula-fed infants [12].
Mothers who breastfeed are likely to gain both short- and long-
term beneﬁts in body weight change. Observational studies show
favourable effects on return to pre-pregnancy weight and
metabolic proﬁles [11,13–15]. Data from the North American
CARDIA study [16] have demonstrated that longer duration of
lactation is associatedwith lower incidence ofmetabolic syndrome
many years after weaning. Bobrow et al. [17] reported favourable
associations with previous breastfeeding among postmenopausal
women in the UK Million Women Study; at every parity level, the
mean standardised BMI was signiﬁcantly lower among women
(mean age 57.4 years) who had previously breastfed, decreasing
[(Fig._7)TD$FIG]
• Measure the waist circumference at th
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distributed
Fig. 7. Measurement protocol for0.22 kg/m2 for every 6 months of breastfeeding. There is, however,
some inconsistency in results from intervention studies –
including a large cluster-randomised trial of 17,046 women from
Belarus, which reported that women randomly assigned to a
successful breastfeeding intervention did not have lower adiposity
after 11.5 years follow-up [18].
2. Association with cancer
2.1. Cancer cases attributable to weight gain, overweight and obesity
Renehan et al. [19] estimated the incident cancer burden
attributable to excess body mass in 30 European countries from
data available in 2008. The estimated population-attributable risk
(PAR) due to overweight and obesity was 3.2% (2.1–4.3%) in men
and 8.6% (5.6–11.5%) in women. Country-speciﬁc data have been
estimated for the UK by Parkin et al. [20] who suggest that an
estimated 17,294 excess in cancer cases occurring in 2010 were
due to overweight and obesity (5.5% of all cancers, 4.1% inmen and
6.9% in women).
More recent UK preventability estimates from the World
Cancer Research Fund (WCRF) [21] for all nine sites – oesophagus,
colorectum, gall bladder, pancreas, breast (postmenopausal),
endometrium, ovaries, kidney and prostate (advanced) – to which
obesity is related [6] indicate that 4–38% of these cancers (depend-
ing on site and gender) can be attributed to excess weight.
2.2. Cancer types associated with overweight and obesity
Numerous observational studies have associated different
measures of adiposity and excess body weight (notably self-
reported BMI and waist circumference) with increased risks of
several cancers. The evidence has increased over the last 10 years.
In 2002, a working group of experts convened by the International
Agency for Research on Cancer (IARC) concluded that in humans
therewas sufﬁcient evidence that avoiding overweight and obesity
reduces the risk of cancers of the colorectum, endometrium, kidney
(renal cell), oesophagus (adenocarcinoma) and postmenopausal
breast cancer [22]. In 2007, a major review of food, nutrition,
physical activity and cancer prevention, the World Cancere end of several consecutive natural 
 midpoint between the top of the iliac 
lpable rib in the mid axillary line
vel parallel to the floor, at the largest 
h-resistant tape that is wrapped snugly 
 that the tape is constricting. Keep the 
 point of measurement
ht during the measurement, with arms 
read apart and body weight evenly 
waist and hip circumference.
Table 2
Proposed cut-off points and risk of metabolic complications.
Indicator Cut-off points Risk of metabolic
complications
Waist circumference >94cm (M); >80 cm (W) Increased
Waist circumference >102 cm (M); >88cm (W) Substantially
increased
Waist–hip ratio 0.90 (M); 0.85 (W) Substantially
increased
A.S. Anderson et al. / Cancer Epidemiology 39S (2015) S34–S45S40Research Fund/American Institute for Cancer Research Second
Expert Report, judged that the evidence of a causal associationwith
excess body fatness was convincing for those cancers [23]. These
associations were conﬁrmed by a meta-analysis of prospective
cohort studies [24], in which the positive association with BMI
became evident for some other cancers including thyroid, liver,
leukaemia, malignant melanoma, multiple myeloma and non-
Hodgkin lymphoma. Other recent quantitative summaries of
observational prospective studies have provided further evidence
of positive associations between BMI and gastric cardia cancer [25]
and advanced prostate cancer [26,27]. In the observational studies,
most of the risk increases are in the range of 10–30% for an increase
of 5 kg/m2 of BMI, and obese subjects have approximately a 1.5–
3.5-fold increased risk of developing the cancers for which an
association has been observed with body fatness, compared with
normal-weight subjects (Table 3).
The existing data indicate that the inﬂuence of excess body
fatness on the risk of cancer may differ between men and women,Table 3
Summary of estimated associations between body mass index (BMI) and risk of some ca
Experts of the 2007 WCRF-AICR Second Expert Report and the CUP).
Men
Studies Risk ratio*
(95%CIs)
I2 (%)§
Convincing
Oesophageal adenocarcinoma 5 1.52 (1.33–1.74) 24
Pancreas 14 1.13 (1.04–1.22) 45.6
Colon 22 1.21 (1.16–1.27) 49.9
Rectum 18 1.10 (1.05–1.15) 0
Endometrium –
Post-menopausal breast cancer –
Kidney 13 1.27 (1.21–1.33) NA
Probable
Gallbladder cancer 4 1.09 (0.99–1.21) 0
Ovarian cancer – – –
Limited suggestive
Liver 11 1.26 (1.11–1.44) 79.1
–
Limited, no conclusion
Leukaemia 7 1.08 (1.02–1.14) 0
Malignant melanoma 6 1.17 (1.05–1.30) 44
Multiple myeloma 8 1.15 (1.05–1.25)
Non-Hodgkin lymphoma 8 1.09 (1.04–1.14) 0
Thyroid cancer 4 1.33 (1.04–1.70) 77
Advanced prostate cancer 13 1.09 (1.02–1.16) 38.1
Pre-menopausal breast cancer
Gastric 8 0.97 (0.88–1.06) 35
Cardia gastric 7 1.32 (1.07–1.64) 81.9
Lung 11 0.76 (0.70–0.83) 63
From WRCF Continuous Update Project (CUP) systematic literature reviews [94].
* Risk ratios estimates for an increase of 5 kg/m2 of BMI.
§ The I2 statistic describes the proportion of total variation in study estimates that i
variability in point estimates, and high heterogeneity for substantially more than 50%.and according to subtypes within a speciﬁc cancer. Stronger
associations have been observed in men for colon cancer, and in
women for gallbladder cancer. As for cancer subtypes, stronger
associations for breast cancer have been observed for the
oestrogen- and progesterone-receptor-positive tumours [28], for
type I endometrioid tumours rather than for type II [29], and –
although the evidence is still limited – for cardia gastric
adenocarcinomas rather than non-cardia gastric malignancies
[25] and for the papillary subtype of thyroid carcinoma [30]. Men-
opausal hormone therapy use may modify the association of body
fatness with hormone-related cancers in women, with larger
relative risks (but not absolute risks) observed in never users of
hormone therapy for breast [24], endometrial [29] and ovarian
cancers [31]. These patterns are complex. Taking breast cancer as
an example, the lowest risk group includes leanwomenwho do not
takemenopausal hormone therapy; obese womenwho do not take
menopausal hormone therapy have a higher risk, as do women
who take menopausal hormone therapy regardless of whether or
not they are obese [32].
Waist-to-hip ratio or waist circumference have been inter-
preted as measures of central adiposity but may also be markers of
overall adiposity. In most studies these measures have shown
associationswith cancer that are similar to those for BMI. However,
some studies have reported associations of waist and waist-to-hip
ratio independent of BMI for some cancers [33], and in a
longitudinal study [34] visceral adiposity measured by using
multidetector computed tomography was associated with overall
risk of cancer after adjustment for generalised adiposity. These
results suggest that the inﬂuence of visceral adiposity on cancer
risk may be at least partially independent of total body adiposity;ncers in prospective studies by strength of the evidence (as judged by the Panels of
Women
Studies Risk ratio
(95% CIs)
I2 (%)§ Reference
3 1.51 (1.31–1.74) 0 Renehan et al. [24]
15 1.10 (1.04–1.16) 41.8 WCRF–CUP SLR, 2012 [95]
24 1.10 (1.05–1.15) 52.7 WCRF–CUP SLR, 2010 [95]
18 1.05 (1.00–1.10) 32 WCRF–CUP SLR, 2010 [95]
25 1.18 (1.08–1.29) 0 WCRF–CUP, SLR 2013 [95]
19 1.12 (1.07–1.18) 59.8 WCRF–CUP, SLR 2008 [95]
15 1.33 (1.27–1.40) NA Ildaphonse et al. [91]
Renehan et al. [24]
Mathew et al. [92]
2 1.59 (1.02–2.47) 67 Renehan et al. [24]
25 1.06 (1.02–1.11) 55% WCRF–CUP, SLR 2014 [95]
5 1.07 (0.55–2.08) NA Wang et al. [96]
WCRF–CUP SLR, 2013 [95]
7 1.17 (1.04–1.32) 80 Renehan et al. [24]
5 0.96 (0.92–1.01) 39 Renehan et al. [24]
10 1.10 (1.05–1.15) Wallin and Larsson [93]
10 1.07 (1.00–1.13) 44.1 Larsson and Walk [94]
3 1.14 (1.06–1.23) 5 Renehan et al. [24]
– Discacciati et al. [26]
16 0.92(0.87–0.97) 50.1 WCRF–CUP, SLR 2008 [95]
5 1.04 (0.90–1.20) 4 Renehan et al. [24]
(men and women combined) Chen et al. [25]
6 0.80 (0.66–0.97) 84 Renehan et al. [24]
s due to heterogeneity. Low heterogeneity might account for less than 30% of the
A.S. Anderson et al. / Cancer Epidemiology 39S (2015) S34–S45 S41however, the public health relevance may be limited because the
main determinant of total visceral adiposity is overall adiposity
itself.
2.3. Mechanisms linking excess body weight to cancer
Chronic positive energy balance – due to excess energy intake
and/or low energy expenditure – can lead to obesity and its
associatedmetabolic alterations, such as increased levels of insulin
and changes in the bioavailabilty of insulin-like-growth factor
(IGF)-I and steroid hormones. Adipose tissue is now recognised as
metabolically active and a source of adipose-tissue-derived
hormones and cytokines (adipokines) such as leptin, adiponectin
and inﬂammatory cytokines. These metabolic alterations have
been implicated as key contributors to the effects of obesity on
cancer incidence through mechanisms that may be general
(operating for several cancer sites) or cancer-speciﬁc [35,36].
The increased risk of postmenopausal breast cancer in obese
women is generally explained by the higher rates of conversion of
androgenic precursors to oestradiol through the activity of
adipose-tissue aromatase. After menopause, when ovarian
oestrogen production stops, the adipose tissue becomes the
major source of endogenous oestrogens. Further, obesity-related
hyperinsulinaemia inhibits hepatic secretion of sex-hormone-
binding globulin. Both effects result in an increase in bioavailable
oestradiol and testosterone [37]. Alterations in endogenous
hormone metabolism may also provide the main links between
obesity and endometrial cancer risk. The ‘unopposed oestrogen’
hypothesis proposes that endometrial cancer may develop as a
result of the mitogenic effects of oestrogens when these are
insufﬁciently counterbalanced by progesterone [38]. There is
abundant experimental evidence from in vitro and animalmodels
that oestrogens increase endometrial cell proliferation, inhibit
apoptosis, and stimulate the local synthesis of IGF-I in endome-
trial tissue [35].
Insulin or hyperinsulinaemia stimulate the proliferation of
tumour cells in vitro and in animal studies and lead to increased
growth of colon, breast, prostate, and bladder cancers [39]. In
prospective epidemiological studies, increased risks of colon [40],
pancreatic [41], endometrial [42], and postmenopausal breast [43]
cancers have been observed in relation to higher levels of
circulating C-peptide levels, a biomarker of insulin secretion.
Indirect evidence for a role of insulin on cancer development is
provided by studies showing that type 2 diabetic patients who get
insulin therapy or drugs to stimulate insulin secretion have a
signiﬁcantly higher incidence of cancer than those who get
metformin, an antidiabetic drug that reduces glucose production in
the liver [44,45]. Hyperinsulinaemia could also promote carcino-
genesis indirectly by increasing the levels of circulating free IGF-I
that has mitogenic and anti-apoptotic activity [39]. In epidemio-
logical studies higher circulating concentrations of IGF-I are
associated with increased risk of prostate [46] and colorectal,
pre- and postmenopausal breast cancers [47,48]. Adiponectin and
leptin are the most abundant adipokines. Although studies have
not been entirely consistent, leptin has been shown to be
mutagenic, pro-inﬂammatory, anti-apoptotic, and pro-angiogenic;
adiponectin is inversely related to BMI and visceral adiposity, may
stimulate apoptosis and inhibit angiogenesis and cell migration. In
prospective studies, adipokines have been found to be associated
with risk of cancers of the breast [49], endometrium [50] and colon
[51]. Leptin enhances the production of inﬂammatory factors, and
different pathways link inﬂammation and cancer by a number of
oncogenes [51].
The increase in risk of adenocarcinoma of the oesophagus
through the effects of obesity is thought to be due largely to reﬂux
of stomach contents into the lower oesophagus [52,53].3. Justiﬁcation for recommendation
3.1. The importance of obesity in prevention
Diet (including alcohol) [54,55] and physical inactivity [56] are
both directly implicated in the aetiology of cancer, as well as being
indirect contributors via their impact on energy balance and
contribution to weight gain. It is useful, however, to consider the
relative contribution of each factor.
Parkin et al. [20] estimated the fraction of all cancers occurring
in the UK in 2010 that could be attributed to suboptimal past
exposures of 14 lifestyle and environmental risk factors. The
relative importance of exposures differed by sex. In men,
overweight and obesity accounted for 4.1% of cancers, compared
to 4.6% for excess alcohol consumption and 0.4% for insufﬁcient
physical activity. In women, overweight and obesity accounted for
6.9% of cancers, compared to 3.3% for excess alcohol and 1.7% for
insufﬁcient physical activity. Insufﬁcient intake of fruit and
vegetables was also estimated to cause 6.1% of cancers in men
and 3.4% of cancers in women.
In a recent international review of preventability estimates,
WCRF (2014) [23] report that of the nine cancer sites in which
excess body fat has been identiﬁed as a risk factor, ﬁve have no
other identiﬁable direct diet and physical activity factors – kidney,
pancreas, gall bladder, ovaries, prostate (advanced) – and in the UK
excess body fat is responsible for 19%, 15%, 16%, 4% and 10% of
cancers respectively in these sites. In oesophageal cancer, physical
activity has not been shown to be directly related to the aetiology,
but the impact of alcohol intake (51%) exceeds both the
contribution of excess body fat (31%) and dietary vegetables and
fruit (26%). In cancer of the endometrium, body fatness accounts
for 38% with a further 10% contributed by low levels of physical
activity with no dietary factors. In breast cancer, alcoholic drinks
make the dominant contribution to preventability (22%), followed
by excess body fat (16%) and low physical activity (12%). Revised
estimates for colorectal cancer [21] suggest that body fat accounts
for 14% of the disease, followed by dietary factors – low intake of
foods containing ﬁbre, and high intakes of red and processed meat
(27%) – and low physical activity (16%).
3.2. Body weight in cancer survivors
After (pre- and post-menopausal) breast cancer diagnosis,
obese women have on average a 33% higher risk of total (95%CI:
21–47%) and breast-cancer-speciﬁc mortality (95%CI: 19–50%)
compared to non-obese women [57]. However, a recent review on
breast cancer survivors [58] fromWCRF International suggests that
more work is needed to examine the relationship between
survivorship and obesity because of inadequate ascertainment,
reporting and correction of potential confounders (notably stage of
disease or type of treatment).
Mortality after ovarian cancer is 17% (95%CI: 3–34%) higher
among obese compared to non-obese women [59]. Although the
number of studies is still small, there is emerging evidence that
higher BMI is associated with poorer cancer-speciﬁc mortality
from endometrial cancer [60]. Obesity has been consistently
associatedwith prostate cancermortality in cohort studies [61,62],
and a meta-analysis by Cao and Ma [63] reported that a 5 kg/m2
increase in BMI was signiﬁcantly associated with a 21% increased
risk of biochemical recurrence of the disease. See also the recent
review on prostate cancer from WCRF/AICR [27].
For colorectal cancer, poorer outcomes have been reported in
obese patients with BMI>35 kg/m2with up to a 38% increased risk
of recurrence and a 36% increased risk of disease-speciﬁc mortality
[64]. Little association has been demonstrated between post-
diagnosis changes in weight or BMI on cancer recurrence and
A.S. Anderson et al. / Cancer Epidemiology 39S (2015) S34–S45S42survival, suggesting that pre-diagnosis obesity status may be a
more important inﬂuence on cancer outcomes [65,66].
Many cancer patients increase in weight after diagnosis and
during treatment, and they commonly experience adverse changes
in body composition – including loss of lean bodymass and gain of
adipose tissue. Weight gain is associated with chemotherapy,
increased BMI at diagnosis, and younger age, andmay in part relate
to decreased physical activity during treatment [67]. Weight gain
can also contribute to psycho-social distress.
No long-term trials of weight loss and cancer recurrence have
yet been reported. However, two US randomised trials of dietary
modiﬁcations on cancer outcomes in breast cancer survivors have
provided indirect evidence that weight loss after diagnosis could
lead to lower rates of recurrence. The WINS (Women’s Interven-
tional Nutrition Study) trial [68] reported a 24% reduction in the
risk of recurrence at 5 years in breast cancer survivors randomly
assigned to a low-fat intervention group. The intervention
group lost an average of 6 lb (4% of body weight) compared
with controls, and demonstrated signiﬁcantly lower rates of
recurrence (HR, 0.76; 95%CI, 0.60–0.98) notably among women
with oestrogen-receptor-negative disease (HR, 0.58; 95%CI, 0.37–
0.91).
A number of lifestyle intervention trials in cancer survivors
have demonstrated that cancer survivors aremotivated and able to
make dietary and lifestyle modiﬁcations and to lose clinically
relevant amounts of body weight. Favourable outcomes include
reduction in co-morbidities and improvements in quality of life,
ﬁtness, and fatigue. There may be additional reasons for focusing
on weight loss in cancer survivors, including co-morbidities such
as cardiovascular disease and diabetes, treatment side-effects, and
reduction in the risk of second malignancies. For cancer survivors,
weight loss programmes for the overweight/obese patient should
embrace both dietary and physical activity components which
meet cancer prevention guidelines.
3.3. Avoiding weight-related co-morbidities (diabetes and heart
disease)
Co-morbid chronic diseases are common in persons with
cancer, and the disease and its treatment are associated with an
increased risk for co-morbid conditions including heart disease,
diabetes, and stroke [69]. It is likely that many pre-diabetic
metabolic changes (notably insulin resistance) may also increase
cancer risk. Type 2 diabetes is positively associated with cancers of
the colon, breast (postmenopausal) and pancreas. Patients with
type 2 diabetes are at increased risk of cancers of the liver,
pancreas, endometrium, colorectum, breast, and bladder [70–
72]. Current estimates show an overall hazard ratio (HR) of 1.23 for
breast cancer incidence, and 1.26 for colorectal cancer incidence in
patients with diabetes compared to those without diabetes
[73]. Body weight reduction has been demonstrated to show
proven beneﬁt with regard to risk reduction of type 2 diabetes and
cardiovascular disease, and a comprehensive programme of
lifestyle modiﬁcation – which includes diet, exercise, and
behavioural techniques – has been demonstrated to achieve
successful weight loss and avoidance of weight gain.
3.4. Body weight in older people
Excess body weight is associated with increased total mortality
[74]. In a large prospective study in 10 European countries, the
lowest risks of death related to BMI were observed at a BMI of
25.3 kg/m2 for men and 24.3 kg/m2 for women [75]. In older
people, stable body weight is a predictor of lower subsequent
mortality. Weight loss is associated with increased mortality (in
the short term) and weight gain (>1 kg), especially amongst theoverweight or obese, is also associatedwith increasedmortality (in
the long term) [76]. Ageing is associated with an increase in
adiposity (fat mass) and a loss of muscle (fat free) mass
(sarcopenia). Sarcopenia is associated with poor muscle strength,
functional impairment and disability, and greater morbidity from
cancer, stroke and coronary heart disease [77]. Prevalence
estimates of sarcopenia range from 5 to 15% in people aged 60–
70 years and from 11 to 50% in those aged over 80 years, with
women at greatest risk. Simultaneous occurrence of obesity and
sarcopenia (sarcopenic obesity) is thought to elevate morbidity
risk and may be masked by high BMI.
3.5. Body weight in childhood
Growth in infancy is inﬂuenced by birth weight and early
feeding experiences which in turn inﬂuence growth patterns, the
so-called ‘adiposity rebound’ (period of increasing BMI after the
early childhood nadir, which usually occurs at about 6 years of age)
and body fatness in childhood. The development of overweight in
childhood appears to track into adult life [78], and although it is
recognised that there is a dearth of longitudinal studies that
examine the development of excess body weight in childhood and
adolescence, a recent review has reported a positive association
between genetic factors and physical activity, but an inconsistent
association with dietary intake [79].
Childhood BMI has been shown to be associated with adult
adiposity [80]; thus interventions which prevent or reduce excess
weight gain in childhood provide a window of opportunity for
overall cancer risk reduction. The evidence for the relationship
between childhood obesity and cancer in adult life is inconsistent.
One UK cohort study reported that the overall risk of adult cancer
was increased with increased childhood BMI, particularly in
smoking-related cancers [81]. There is limited evidence in relation
to higher childhood weight and later development of colorectal
and kidney cancer [82]. In breast cancer, greater body fatness
during childhood and adolescence appears to be associated with a
reduced risk of breast cancer in later life (particularly premeno-
pausal breast cancer) [83]. The reasons for this are unclear but are
thought to relate to endogenous sex hormone levels and greater
anovulation in overweight adolescents [84].
3.6. Intentional weight loss and cancer risk
There is as yet no clear demonstration that avoiding excess
body weight can reduce cancer risk. The number of studies on
intentional weight loss is sparse, but at least six studies (including
three surgical studies) have reported that cancer incidence is
reduced after intentional weight loss in individuals with excess
weight, and they suggest that the time needed to obtain a
reduction in cancer incidence could be relatively short (longest
follow-up was 10.9 years) [85]. Estimates for reduction in overall
cancer incidence inmales and females from bariatric surgery are in
the order of 30%. Risk reduction is greatest for obesity-related
cancers and in women. Apart from the reduction in incidence for
overall cancer, signiﬁcant ﬁndings have mostly been reported for
postmenopausal breast cancer and endometrial cancer [86]. In
breast cancer, there is increasing interest in exploring the
beneﬁcial effects of weight loss in overweight and obese, post-
menopausalwomenwith respect to decreased levels of oestrogens,
insulin, and leptin, and increased levels of sex-hormone-binding
globulin (SHBG) as mediators of cancer risk reduction [87].
There are limited observational data on the impact of
intentional weight loss on colorectal cancer [88], although one
Austrian study [89] has reported that weight loss (>0.10 kg/m2/
year) was strongly associated with reduced risk of colorectal
cancer in men (HR = 0.50, 95%CI, 0.29–0.87).
Box 1. European [3_TD$DIFF]Code [4_TD$DIFF]Against [5_TD$DIFF]Cancer.
[6_TD$DIFF]EUROPEAN CODE AGAINST CANCER
12 ways to reduce your cancer risk
1. Do not smoke. Do not use any form of tobacco
[1_TD$DIFF]2. Make your home smoke [7_TD$DIFF] free. Support smoke-free policies in your
workplace
[1_TD$DIFF]3. Take action to be a healthy body weight
[1_TD$DIFF]4. Be physically active in everyday life. Limit the time you spend sitting
[1_TD$DIFF]5. Have a healthy diet:
 [8_TD$DIFF] Eat plenty of whole grains, pulses, vegetables and fruits
[1_TD$DIFF] [9_TD$DIFF] Limit high-calorie foods (foods high in sugar or fat) and avoid sugary
drinks
[1_TD$DIFF] [10_TD$DIFF] Avoid processed meat; limit red meat and foods high in salt
[1_TD$DIFF]6. If you drink alcohol of any type, limit your intake. Not drinking alcohol is
better for cancer prevention
[1_TD$DIFF]7. Avoid too much sun, especially for children. Use sun protection. Do not
use sunbeds
[1_TD$DIFF]8. In the workplace, protect yourself against cancer-causing substances by
following health and safety instructions
[1_TD$DIFF]9. Find out if you are exposed to radiation fromnaturally high radon levels in
your home [11_TD$DIFF]; [12_TD$DIFF]take action to reduce high radon levels
[1_TD$DIFF] 0. For women:
 [13_TD$DIFF] Breastfeeding reduces the mother’s cancer risk. If you can, breastfeed
your baby
[1_TD$DIFF] [14_TD$DIFF] Hormone replacement therapy (HRT) increases the risk of certain
cancers. Limit use of HRT
[1_TD$DIFF] 1. Ensure [2_TD$DIFF] your children take part in vaccination programmes for:
 [15_TD$DIFF] Hepatitis B (for newborns)
[1_TD$DIFF] [16_TD$DIFF] Human papillomavirus (HPV) (for girls)
[1_TD$DIFF] 2. Take part in organised cancer screening programmes for:
 [17_TD$DIFF] Bowel cancer (men and women)
[1_TD$DIFF] [18_TD$DIFF] Breast cancer (women)
[1_TD$DIFF] [19_TD$DIFF] Cervical cancer (women)
[1_TD$DIFF] he European Code Against Cancer focuses on actions that individual
citizens can take to help prevent cancer. Successful cancer prevention
requires these individual actions to be supported by governmental policies
and actions.
A.S. Anderson et al. / Cancer Epidemiology 39S (2015) S34–S45 S43In conclusion, taking the available evidence relating to excess
body fat and cancer, the Nutrition Working Group of the 4th
edition of the European Code against Cancer (Box 1) has developed
the following recommendation: ‘Take action to be a healthy body
weight’.
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